Latest news with #ChrisChen
Yahoo
4 days ago
- Business
- Yahoo
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
Best ESG rating tier of negligible-risk with a top 1% global ranking score Industry and Regional ESG Top-Rated Company for five consecutive years Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, July 16, 2025 /PRNewswire/ -- WuXi Biologics ( a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has elevated its Morningstar Sustainalytics ESG rating score to the highest negligible-risk tier, demonstrating its leadership in the global pharmaceutical industry. Sustainalytics is a leading ESG data, research, and ratings firm that supports global investors with their development and implementation of responsible investment strategies. Its 2025 ESG Risk Ratings—covering more than 15,000 companies across different industries worldwide—evaluates over 20 material ESG issues through over 200 indicators and categorizes rating results across five risk levels, from the best negligible to the worst severe. Under the two-dimensional assessment framework, WuXi Biologics achieved the lowest level of risk exposure and was given the strongest risk management score, placing it in the negligible-risk tier with a top 1% global ranking. In addition, for the fifth consecutive year, the company has been recognized by Morningstar Sustainalytics as an Industry and Regional ESG Top-Rated Company. Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very pleased to have achieved the negligible-risk rating from Morningstar Sustainalytics. It is a reflection of and recognition for WuXi Biologics' continuous commitment to enhancing sustainability capabilities. As a global leader in Green CRDMO, we are focused not only on delivering our own ESG excellence but also on enabling partners worldwide to fulfill their ESG commitments, collaborating with all stakeholders to promote responsible practices throughout the entire value chain." As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), the company proactively contributes to advocating sustainability and has earned widespread recognitions for its efforts. It has been granted a MSCI AAA rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A list" and given an A- CDP Climate Change leadership-level score since 2023; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating. About Morningstar SustainalyticsMorningstar Sustainalytics is a leading ESG data, research, and ratings firm that supports investors around the world with the development and implementation of responsible investment strategies. For more than 30 years, the firm has been at the forefront of developing high-quality, innovative solutions to meet the evolving needs of global investors. Today, Morningstar Sustainalytics works with hundreds of the world's leading asset managers and pension funds who incorporate ESG information and assessments into their investment processes. The firm also works with hundreds of companies and their financial intermediaries to help them consider material sustainability factors in policies, practices, and capital projects. Morningstar Sustainalytics has analysts around the world with varied multidisciplinary expertise across more than 40 industry groups. For more information, visit About WuXi BiologicsWuXi Biologics (stock code: is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects). WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: Contacts ESG esg@ Media PR@ View original content: SOURCE WuXi Biologics
Business Insider
09-07-2025
- Business
- Business Insider
Just starting your investing journey? Here's what the pros say about how to split your money between single stocks and ETFs.
A friend who's just starting out investing and opened up their first brokerage account asked me the other day: How much should they be putting into single stocks versus ETFs that track the broader market? It's a good question. Individual stocks, while riskier than diversified ETFs, have the potential for more explosive growth. With stories of retail investors striking it rich with stocks like Nvidia, Apple, Microsoft, and Palantir in recent years, trying your hand at stock picking is tempting. Seeking an informed view, I asked a few financial experts what they think. Questions like these are always tough to answer in generalities — the right answer depends on someone's individual circumstances, goals, risk tolerance, and timeline. But even with the assumption that the investor is in their 20s and has a long time horizon, the answer was unanimous among the four experts I spoke with — It's better to just have your equity exposure in passive funds. There are several reasons behind their advice. A big one is the amount of time it takes to research which stocks to buy. "If you're starting to build a portfolio today, you're much better off focusing your time and energy and attention on your career and making money and putting more money away and just keeping it diversified," said Jason Browne, a Chartered Financial Consultant and the founder of Alexis Investment Partners. "In other words, make sure that you're participating in the growth of the stock market over time instead of spending your time trying to pick individual winners." Then there's the competition, who you're buying and selling from: Wall Street investors, whose full-time job is watching the market. "Competing with all those people down there, the tens of thousands and hundreds of thousands of people who have their eyes glued to the screen all day, figuring out how to make a buck," said Chris Chen, a Certified Financial Planner and wealth strategist at Insight Financial Strategists. "As individuals, it's very difficult to do that." The odds of beating the market are also pretty low, no matter who you are. Even the Wall Street professionals, on average, don't have an impressive track record. Only 15% of large-cap funds have beaten the S&P 500 over the last decade, according to SPIVA data from December 2024. That number is about the same for the last three-year period. During 2024, only 34% of funds beat the index. A 2024 study from Arizona State University professor Hendrik Bessembinder also found that around 51% of 29,078 US stocks listed since 1925 have lost value over the lifetimes with a median return of -7.4%. 3 tips for stock picking Those numbers aren't exactly appetizing. But if you're still convinced you can pick winners, or at least want the thrill of trying, there are a few tips experts recommend keeping in mind. First, allocate a small percentage of your portfolio to individual stocks — something like 5%-10%. "When you're younger, you can take bigger swings," said Tyler Meyer, a certified financial planner and the founder of Retire to Abundance. "But generally speaking, I would stay away from more than 5% into individual investments." Second, come up with a method for picking your stocks. While it's probably overly time consuming to do the sort of financial analysis done on Wall Street, there are theories you can go off of, Chen said. For example, you might consider the Dogs of the Dow theory, Chen said, which posits that the 10 stocks in the Dow Jones Industrial Average with the highest dividends in a given year are the cheapest in the index, and are therefore primed for outperformance in the following year. Or you could wait for blue-chip stocks like Apple, Meta, and Alphabet to undergo and significant correction and buy the dip, Browne said. "Every year for whatever reason they fall out of bed," Browne said. "You do have the ability then to add a little bit of value by just trading around the normal trading patterns of those names, because they are so volatile." Another, less scientific option (but touted by investing icon Warren Buffett) is to buy what you understand. Business Insider recently profiled several everday investors who made winning stock picks based on observations in their day-to-day live. Third and finally, be prepared to hold onto a stock for at least three-to-five years. "Statistically, that's when you're going to see the increases in stocks," said Melissa Cox, a Certified Financial Planner and the owner of Future-Focused Wealth. "It's not an overnight thing."
Associated Press
09-06-2025
- Business
- Associated Press
WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
CHENGDU, China, June 9, 2025 /PRNewswire/ -- WuXi Biologics ( a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has kicked off construction of its new microbial manufacturing site for commercial production in the Wenjiang district of Chengdu, a renowned, vibrant hub for pharmaceutical development. Spanning an area of 95,000 square meters, the new site is dedicated to a drug substance (DS) facility and a drug product (DP) facility for commercial manufacturing, encompassing a wide array of modalities, such as peptides,antibody fragments, plasmid DNA, enzymes, cytokines, and virus-like particles (VLPs). Scheduled to complete GMP release for production by the end of 2026, the site will be equipped with a 15,000L fermenter, enabling an annual production capacity of 80 to 110 DS batches. In the long run, capacity will be able to expand to 60,000L. Notably, the facility will house China's first dual-chamber lyophilization production line alongside a vial filling line, with overall DP manufacturing capacity exceeding 10 million vials annually, a significant enhancement of WuXi Biologics' commercial manufacturing capabilities for the global market. The state-of-the-art facilities will feature WuXi Biologics' recently launched microbial expression platform EffiXTM for the development and manufacturing of biologics with high yield, consistent quality, and superior stability and scalability, achieving titers that exceed 15 g/L for non-mAb recombinant proteins. Equipped with advanced automated systems to help ensure regulatory compliance, operational efficiency, and uncompromising quality, the facilities have also been designed with a strong focus on energy conservation and sustainability. Through the optimization of process development approaches and implementation of comprehensive carbon tracking mechanisms, the company aims to minimize its environmental footprint while maintaining high production standards. WuXi Biologics will utilize the manufacturing site in Chengdu to produce VISEN Pharmaceuticals' inaugural commercial product, Lonapegsomatropin, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency (PGHD). In addition to this landmark partnership, the company has also established strategic partnership with industry-leading biotech firm Virogen Biotechnology. These collaborations — centered around commercial manufacturing operations — underscore WuXi Biologics' expanding portfolio of partnerships and its drive to meet the growing demand for advanced biologic therapies. Dr. Chris Chen, CEO of WuXi Biologics, commented, 'We are excited to kick off the construction of Chengdu microbial manufacturing site, a powerful enhancement to add to our comprehensive end-to-end microbial solutions. With the booming global market for microbial products presenting unprecedented potential for next-generation therapies, our Chengdu site — with its robust production scale and cutting-edge technologies — is ideally positioned to capitalize on this trend. The strategic partnerships with leading pharmaceutical companies not only validate the capabilities of our new site but also represent a pivotal milestone in our unwavering commitment to accelerating the development and delivery of innovative therapies to patients worldwide.' View original content: SOURCE WuXi Biologics
Yahoo
17-05-2025
- Business
- Yahoo
WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for Gaucher disease in China, marks a significant breakthrough for CANbridge Pharmaceuticals and WuXi Biologics in advancing R&D of innovative rare disease therapeutics in China. Velaglucerase-beta for injection is the first innovative biological product in China to pass segmented manufacturing inspection. WUXI, China and SHANGHAI, May 16, 2025 /PRNewswire/ -- WuXi Biologics ( a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its partner CANbridge Pharmaceuticals on the approval of its innovative velaglucerase-beta for injection (Gaurunning) by the China National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above and adults with type I and type III Gaucher disease. This marks China's first and only locally developed enzyme replacement therapy (ERT) for Gaucher disease. Gaucher disease is a rare inherited genetic lysosomal storage disorder characterized by clinical manifestations such as hepatosplenomegaly, anemia, bone pain, and neurological symptoms, which can be life-threatening in severe cases. Recombinant human glucocerebrosidase ERT has been the standard treatment for Gaucher disease for 30 years, significantly improving major non-neurological signs and symptoms, as well as improving the quality of life for patients. It is estimated that the global prevalence of Gaucher disease is 0.7 to 1.75 per 100,000 people. Gaucher disease has been included in China's "First List of Rare Diseases". Velaglucerase-beta for injection is the first collaboration project on rare diseases between CANbridge and WuXi Biologics, advancing from concept to commercialization by leveraging WuXi Biologics' leading integrated technology platform. The project utilized innovative technology to construct high-expression cell line and achieved significant improvements in both yield and quality through WuXiUPTM, an ultra-high productivity continuous bioprocessing platform of WuXi Biologics. The overall yield increased by more than 110 times, and the specific enzyme activity increased by more than 50%, ensuring the affordability for Gaucher disease patients. Additionally, WuXi Biologics developed cell-based bioassay methods for commercial product release and stability testing, addressing the technical challenges of enzyme testing and effectively ensuring product quality control. Additionally, velaglucerase-beta for injection is the first innovative biological product in China to pass segmented manufacturing inspection. Dr. Chris Chen, CEO of WuXi Biologics, stated, "We are honored to enable CANbridge to achieve the significant milestone of approval for velaglucerase-beta for injection, which represents a critical advancement in rare disease drug innovation in China. Developing therapies for rare diseases is a long and challenging journey, requiring relentless joint efforts to bridge the gap between early-stage discovery and patients' access to medication. The successful commercialization of velaglucerase-beta for injection not only reflects CANbridge's decade-long dedication to rare diseases but also exemplifies the value of WuXi Biologics' integrated platform and CRDMO business model. Furthermore, our shared commitment to addressing the unmet clinical needs of rare disease patients has resulted in China's first locally developed ERT for Gaucher disease. We look forward to enabling more global partners to accelerate the development of high-quality rare disease therapies, and making them accessible and affordable for more patients suffering from rare diseases." Dr. James Xue, Founder, Chairman, and CEO of CANbridge Pharmaceuticals, stated, "Enzyme replacement therapy is a crucial part of CANbridge' global pipeline. The approval of velaglucerase-beta for injection in China is a milestone. By leveraging the integrated technology platform, velaglucerase-beta for injection will significantly reduce development costs, making safe and effective domestically produced ERT accessible and affordable for patients. This product is also the first collaboration project between CANbridge and WuXi Biologics in rare diseases. We extend our gratitude to our partners, including WuXi Biologics, who have empowered the development and manufacturing of velaglucerase-beta for injection. This milestone is not only CANbridge' third rare disease drug to be launched following Hunterase® and Livmarli®, but also the first in-house developed commercialized product. In the future, we will continue to focus on the localized research, manufacturing, commercialization, and accessibility of rare disease drugs, bringing innovative treatments to patients in China." Since its establishment, WuXi Biologics has been committed to enabling global innovative biotech companies to accelerate the rare disease drugs from concept to commercialization, benefiting rare disease patients worldwide. As ofthe end of 2024, there are 21 rare disease projects on the company's platform. Additionally, the company actively promotes public awareness and supports the rare disease patient community through various philanthropic initiatives. Its global "Run for Health" campaign has engaged over 2,500 participants to raise awareness for rare diseases. In China, the company's "Rare Disease Student Education Support Program" has provided scholarships to over 100 students affected by rare diseases over the past four years, fostering their academic growth. About Velaglucerase-beta for Injection (Gaurunning) Velaglucerase-beta for injection is the first domestically developed recombinant human glucocerebrosidase ERT in China, now approved for clinical use in treatment of Type I and Type III Gaucher disease patients. Most Gaucher disease patients are Type I and Type III, which are chronic non-neuronopathic and chronic neuronopathic forms, respectively. velaglucerase-beta is administered as an intravenous infusion and is intended to supplement the lack of glucocerebrosidase in the lysosomes of GD patients. The pivotal clinical trial of velaglucerase-beta achieved positive top-line data in August 2024. The velaglucerase-beta pivotal trial is a randomized, double-blind, dose-comparison study designed to evaluate the efficacy, safety, and pharmacokinetics of intravenous velaglucerase-beta administered every other week in newly treated Gaucher Disease (GD) patients, with an extension period. The results demonstrate that the study successfully met its primary efficacy endpoint, showing a statistically significant mean percentage reduction from baseline in spleen volume at nine months for both the 60 U/kg dose (P<0.0001) and the lower 30 U/kg dose (P<0.001). The primary endpoint of this trial protocol has been agreed upon by the CDE. About Gaucher Disease (GD) Gaucher disease, one of the most common lysosomal storage disorders, is a rare inherited genetic metabolic disease caused by autosomal recessive mutations in the GBA gene located on chromosome 1q22 and affects both males and females equally. Gaucher disease is a clinical spectrum that comprises Type 0 (perinatal-lethal), Type I (chronic non-neuronopathic), Type II (acute neuronopathic), and Type III (chronic neuronopathic) forms, with Types I and III surviving into adulthood. Gaucher disease is caused by a deficiency of glucocerebrosidase (acid b-glucosidase), an enzyme that helps break down a cellular membrane glycosphingolipid called glucocerebroside (glucosylceramide) inside lysosomes. As a result, glucocerebroside accumulates primarily in cells of the monocyte-macrophage lineage (Gaucher cells) within certain organs, leading to splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone pain and fractures, and in the most severe forms (perinatal-lethal, Types II and III), early neurological symptoms. For 30 years, recombinant human glucocerebrosidase enzyme replacement therapy (ERT) has been the standard of care for Gaucher disease, with clinical trials and real-world data demonstrating significant improvement in the major non-neurological signs and symptoms of disease and quality of life. There were 3,000 patients with Gaucher disease in China in 2020, according to Frost & Sullivan. Gaucher disease has been included in China's "First List of Rare Diseases." About WuXi Biologics WuXi Biologics (stock code: is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects). WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: About Canbridge CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease. CANbridge has a differentiated drug portfolio, with 3 approved drugs and a pipeline of 8 assets, targeting prevalent rare disease indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. The CANbridge Next-Generation Innovation and Process Development Facility is developing novel, potentially curative, gene therapies for rare genetic diseases, including Pompe disease, Fabry disease, spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD) and other neuromuscular conditions, and collaborates with world-leading researchers and biotech companies. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School, the University of Washington School of Medicine and Scriptr Global. For more on CANbridge Pharmaceuticals Inc., please go to: Contacts Businessinfo@ MediaPR@ View original content: SOURCE WuXi Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
15-05-2025
- Business
- Business Insider
How to invest a lump sum of money at any age
Investing a windfall requires considering age, risk tolerance, and financial goals. Younger investors can afford more risk, while older investors should focus on stability. Consult a financial planner to tailor investment strategies to individual circumstances. It's the age-old question when you suddenly come into a bit of money: What should you do with it? Temptations lurk. That bucket-list trip to St. Bart's. The Mercedes C-Class convertible you've always wanted. A seahorse-shaped potato chip currently going for $105,000 on eBay. Oh, that's just me? While the pull of instant gratification is strong, perhaps you've come to the more responsible decision to invest the money. Even then, it's difficult to know where to put your new lump sum. The answer will differ for everyone, depending on when they'll need the money and what their risk tolerance is. But we thought a general guide may be useful for people of all ages who've just received a chunk of money like a bonus, an inheritance, or a tax return. With the help of Chris Chen, a certified financial planner and the founder of Insight Financial Strategists, we've come up with a plan that investors can think about taking with a new windfall, no matter how old they are. While it's impossible to personalize a plan for each individual, the assumption in this case is that the cash will be put aside for retirement. Disclaimer: this is not specialized financial advice, and each investor should consider their own circumstances and consult a financial professional before making decisions. Check out your suggested path below. 20-29 Open a brokerage account. Not a 401(k) or a Roth IRA — those should be set up with an employer and contributed to regularly. Setting up a separate account with a brokerage firm like Vanguard or Ally will prevent you from having to pay penalties if you need the money before retirement age. Once that's done, allocate 80% of the money to stocks and 20% to bonds. The classic portfolio construction is 60% stocks and 40% bonds, but your longer investing timeline means you can withstand the volatility of the stock market. A 20% allocation to bonds will still provide some downside protection. Within stocks, put most of your money into an index fund like the SPDR Portfolio S&P 500 ETF (SPLG). To diversify, allocate around 5-10% to international stocks through a fund like the Schwab International Equity ETF (SCHF). 30-39 Perhaps you already have a stock portfolio. It's not a bad idea to simply throw a new lump sum into existing positions, or into a broad index fund that will grow over a decadeslong period. It could also be a good opportunity to assess how your portfolio is structured, and think about how you can perhaps rebalance with some international exposure it so you're properly diversified. You may also want to diversify into another asset class: real estate. If it's enough money for a down payment, you could lose the lump sum to buy a home. Mortgage rates admittedly aren't great at the moment, but you can always refinance if rates drop in the future. People increasingly have their first kid in their 30s. If that's the case for you, maybe open a 529 plan for college savings. If you're not a parent yet but plan on being one sometime down the line, you can open up a 529 plan for yourself, as the funds can be used for anyone in your family. 40-49 You're starting to get closer to retirement age, but assuming a retirement age of 65, you still probably have enough time to keep your equity exposure aggressive. Put 80% of the money into an S&P 500 index fund and 20% into bonds through a fund like the iShares Core US Aggregate Bond ETF (AGG). If you're lucky enough to feel like you're pretty well covered on your own retirement needs, you might consider opening up a Roth IRA for your kids, if you have them. 50-59 Retirement is on the horizon, so you should start taking a more cautious and active approach to money management. At this point, it's a good idea to hire a Certified Financial Planner to develop a plan that's unique to your needs. A generally good idea heading into retirement is to start building up a three-year "safe bucket," which is enough living expenses to cover three years. You'll have this money in low-risk, shorter-term bonds. Any leftover money can go into stock-market index funds. Stocks are risky and volatile investments that can be subject to significant downside in a short period of time. That's why it's good to have an investing timeline of at least a few years, or even better, more than a decade. 60+ It's the same advice for those in their 50s: start building up enough funds to cover three years of living expenses. These funds will be invested in safe-haven short-term bonds. Extra money can go into a stock-market index fund, though it may be a good idea to allocate part of your stock portfolio to more defensive areas of the market since your investing timeline starts to shorten. Once you retire, you'll start to sell your bond positions year by year to fund your spending. As you sell the bonds, you'll need to sell an equivalent amount in stock positions to keep your "safe bucket" three years deep. The calculus on how much money you'll need to pull out of your portfolio does start to change a bit once you're able to start claiming Social Security as early as 62.
